Table 1. Clinicopathologic features of patients with different chemotherapy regimens.

	5–FU	Oxaliplatin	P value
Gender			0.858
Male	321	131
Female	219	92
Age at diagnosis, years			0.001
66–70	184	105
71–75	175	70
> 75	181	48
Residence location			0.025
Big Metro	261	127
Metro or Urban	199	77
Less Urban or Rural	80	19
Year of diagnosis			< 0.001
1992–2000	125	0
2001–2004	251	26
2005–2008	164	197
Histologic grade			0.980
Well	35	14
Moderate	360	146
Poor/Undifferentiated	87	37
Unknown	58	26
ypT category			0.398
ypT1–2	146	50
ypT3	367	160
ypT4	27	13
ypN category			0.795
ypN0	339	134
ypN1a	85	34
ypN1b	59	26
ypN2a	36	16
ypN2b	21	13
ypTNM stage			0.315
ypTNM I	113	36
ypTNM II	226	98
ypTNM III	201	89
Intestinal obstruction			0.834
No	484	201
Yes	56	22
HCC risk score			0.503
1st quartile	143	56
2nd quartile	131	45
3rd quartile	152	67
4th quartile	114	55
Number of examined lymph node			0.007
≥ 12	200	106
< 12	340	117
Postoperative radiotherapy			0.001
No	455	208
Yes	85	15

Abbreviation: HCC, Hierarchical Condition Categories; No-chemo, without postoperative chemotherapy; 5-FU, 5-fluorouracil.